Superworth

aTYR PHARMA INC price to book ratio ATYR

Market value divided by the book value of the company's net assets, since 2024.

Today, Nov 2, 2026
0.3×
2-year median
1.4×
Against its 2-year history
1st
percentile: 0 is its lowest day, 100 its highest
2-year range
0.2× to 7.9×
Peer median
1.5×

aTYR PHARMA INC's price to book ratio is 0.3× as of Nov 2, 2026.

That is below its 2-year median of 1.4×, lower than on 99% of days in the last 2 years.

Over that time it ranged from 0.2× in Oct 2026 to 7.9× in Sep 2025.

The median for 7 healthcare stocks of a similar size is 1.5×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far0.3×0.2×1.4×
20250.9×0.8×7.9×
20244.8×1.2×4.8×

Against its peers

Companies in Healthcare nearest aTYR PHARMA INC's size, closest first, today.

CompanyPrice to book ratio
ATYRaTYR PHARMA INC0.3×
NEPHNephros2.9×
ATNMActinium Pharmaceuticals1.5×
APTAlpha Pro Tech0.9×
SPROSpero Therapeutics1.4×
LFVNLifevantage2.2×
ICCCImmucell3.1×
KEQUKewaunee Scientific1.3×
Peer median1.5×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on aTYR PHARMA INC

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.